Develops drugs for autoimmune diseases, including lupus nephritis.
Jun 2026Revenue $312M/yrExpenses $161M/yr
Reached break-even Jan 2025
Figures by year
When did Aurinia Pharmaceuticals become profitable?
Its revenue passed its expenses in Jan 2025. In the 12 months to Jun 2026, revenue was $312M and expenses $161M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $283M | $178M | $105M |
| Dec 2024 | $235M | $240M | −$4.69M |
| Dec 2023 | $176M | $267M | −$91.7M |
| Dec 2022 | $134M | $246M | −$111M |
| Dec 2021 | $45.6M | $226M | −$181M |
| Dec 2020 | $50.1M | $154M | −$104M |
| Dec 2019 | $318K | $91.3M | −$90.9M |
| Dec 2018 | $463K | $55.7M | −$55.2M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.